Literature DB >> 85637

Meningococcal infection and proteolytic control.

J M Stark, N Matthews, H C Ryley, B M Greenwood, L S Lewis, H C Whittle.   

Abstract

Cascade enzyme inhibitors (C1-esterase inhibitor, C3b inactivator, antithrombin III) and other major proteolytic enzyme inhibitors (alpha 1 trypsin inhibitor, alpha 1 chymotrypsin inhibitor, inter-alpha-trypsin inhibitor, alpha 2 macroglobulin) as well as C3 and alpha 1 acid glycoprotein, have been examined in the sera of Nigerian patients suffering from meningococcal infection of varied severity. Patients with meningococcaemia had lower serum concentrations of important inhibitors than did patients with localised meningitic infection. Within the coccaemic group, those who died had the lowest values, notably of antithrombin III and alpha 2 macroglobulin (and also of C3). The clinical end-result of meningococcal infection may be related to the degree of disequilibrium of the linked system of proteolytic control induced by the meningococcal endotoxin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 85637      PMCID: PMC1145527          DOI: 10.1136/jcp.31.12.1177

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Inhibition of proteases in coagulation, kinin-forming and complement systems by alpha2-plasmin inhibitor.

Authors:  M Moroi; N Aoki
Journal:  J Biochem       Date:  1977-10       Impact factor: 3.387

2.  Effects of activated complement components on enzyme secretion by macrophages.

Authors:  H U Schorlemmer; A C Allison
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

3.  Reaction mechanism of the alternative pathway of complement fixation.

Authors:  P J Lachmann; P Nicol
Journal:  Lancet       Date:  1973-03-03       Impact factor: 79.321

4.  Counter-current immunoelectrophoresis in the diagnosis of meningococcal infections.

Authors:  B M Greenwood; H C Whittle; O Dominic-Rajkovic
Journal:  Lancet       Date:  1971-09-04       Impact factor: 79.321

Review 5.  The natural modulation of the amplification phase of complement activation.

Authors:  D T Fearon; M R Daha; J M Weiler; K F Austen
Journal:  Transplant Rev       Date:  1976

6.  Screening for cystic fibrosis by analysis of meconium for albumin and protease inhibitors.

Authors:  H C Ryley; L M Neale; T D Brogan; P T Bray
Journal:  Clin Chim Acta       Date:  1975-10-15       Impact factor: 3.786

7.  Complement and meningococcal infection.

Authors:  B M Greenwood; I I Onyewotu; H C Whittle
Journal:  Br Med J       Date:  1976-04-03

8.  The conversion of C'IS to C'1 esterase by plasmin and trypsin.

Authors:  O D Ratnoff; G B Naff
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

9.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

  9 in total
  1 in total

1.  [Effect of different feeding initiation formulas on very low birth weight infants].

Authors:  Xue-Mei Li; Jing Jiang; Yan Wu; Xiu-Lan Li; Gong-Xue Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.